Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study

Arthritis Care and Research

Volumn 69, Issue 10, 2017, Pages 1484-1494

  Choy, Ernest H ^a   Bernasconi, Corrado ^b   Aassi, Maher ^b   Molina, Jose Fernando ^c   Epis, Oscar Massimiliano ^d  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Centro Integral de Reumatología REUMALAB   (Colombia)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GRAFT INFECTION; HEALTH ASSESSMENT QUESTIONNAIRE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PERICARDIAL EFFUSION; PERITONITIS; PNEUMONIA; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DISABILITY; DRUG SUBSTITUTION; FEMALE; IMMUNOLOGY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; REMISSION; TIME FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISABILITY EVALUATION; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85028929150     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23303     Document Type: Article

References (29)

1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1–26.
2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
3. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50.
4. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86–94.
5. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority trial. Lancet 2016;388:239–47.
6. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425–41.
7. Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, et al. An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford) 2011;50:2093–9.
8. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-α inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013;32:1347–55.
9. Romao VC, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, et al. Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the Rheumatic Diseases Portuguese Register, Reuma.pt. Biomed Res Int 2015;2015:279890.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
11. Actemra (tocilizumab) injection, for intravenous use injection, for subcutaneous use [prescribing information]. South San Francisco (CA): Genentech; 2014.
12. Actemra (tocilizumab). Mississauga (Ontario, Canada): Hoffmann-La Roche Limited; 2015. URL: http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Actemra/Actemra_PM_E.pdf.
13. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Admin Pharm 2006;2:143–51.
14. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:805–10.
15. Bykerk V, Ostor AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012:71:1950–4.
16. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134–42.
17. Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, et al. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol 2014;41:1935–43.
18. Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011;13:R204.
19. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 2012;6:429–64.
20. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Managed Care Specialty Pharm 2015;21:409–23.
21. Haraoui B, Casado G, Theander E, Czirják L, Taylor A, Mikes E, et al. Regional patterns of tocilizumab use, efficacy, and safety in patients with rheumatoid arthritis: interim results from a multinational observational study [abstract]. Ann Rheum Dis 2015;74:1042–3.
22. Jones G, Bird P, Hall S, Littlejohn G, Tymms K, Youssef P, et al. Dispensing of biologics prescribed for the treatment of rheumatoid arthritis in the Australian population [abstract]. Ann Rheum Dis 2015;74:246–7.
23. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, et al. Long-term safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768–80.
24. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94.
25. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238–44.
26. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096–103.
27. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129–135.
28. Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015;74:96–103.
29. Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 2015;17:74.